文献速递胃肠外科围术期管理与 ERAS

腹腔镜袖状胃切除术与Roux-en-Y胃旁路术治疗病态肥胖:SM-BOSS随机试验3年结果

Laparoscopic Sleeve Gastrectomy Versus Roux-Y-Gastric Bypass for Morbid Obesity-3-Year Outcomes of the Prospective Randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS).
PubMed 文献 · Ann Surg · 2017-01-01

SM-BOSS为前瞻性随机多中心试验,纳入217例病态肥胖患者(LSG 107例,LRYGB 110例),比较两种术式3年减重、合并症、生活质量及并发症。结果显示两者减重、生活质量及再手术并发症无显著差异,但LRYGB对胃食管反流病和血脂异常改善更优。

要点

  • LSG与LRYGB在术后3年减重效果相当,多余BMI丢失率无显著差异。
  • LRYGB对胃食管反流病和血脂异常的控制优于LSG。
  • 两组再手术并发症发生率无统计学差异(LSG 9例 vs LRYGB 16例,P=0.15)。

核心结论

  • LSG与LRYGB在术后3年内减重、生活质量和并发症方面效果相当,但LRYGB对胃食管反流病和血脂异常改善更佳。

研究设计与样本

  • 前瞻性随机多中心试验(SM-BOSS),纳入217例病态肥胖患者,随机接受LSG(n=107)或LRYGB(n=110),平均BMI 44±11 kg/m²,平均年龄43±5.3岁,女性占72%,3年随访率97%。

主要发现

  • 多余BMI丢失率在1年(72.3±21.9% vs 76.6±20.9%,P=0.139)、2年(74.7±29.8% vs 77.7±30%,P=0.513)和3年(70.9±23.8% vs 73.8±23.3%,P=0.316)两组相似。
  • 两组合并症均显著减少且效果相当,但胃食管反流病和血脂异常在LRYGB组改善更成功。
  • 两组生活质量在术后1、2、3年均显著提高。
  • 再手术治疗的并发症数量两组无显著差异(LSG 9例 vs LRYGB 16例,P=0.15),保守治疗的并发症数量亦无差异。

临床怎么用

  • 对于病态肥胖患者,LSG和LRYGB均可作为有效术式,选择时需考虑合并症谱,尤其是胃食管反流病和血脂异常者可能从LRYGB更多获益。

局限性

  • 本文为3年中期结果,非最终5年随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Laparoscopic sleeve gastrectomy (LSG) is performed almost as often in Europe as laparoscopic Roux-Y-Gastric Bypass (LRYGB). We present the 3-year interim results of the 5-year prospective, randomized trial comparing the 2 procedures (Swiss Multicentre Bypass Or Sleeve Study; SM-BOSS). METHODS: Initially, 217 patients (LSG, n = 107; LRYGB, n = 110) were randomized to receive either LSG or LRYGB at 4 bariatric centers in Switzerland. Mean body mass index of all patients was 44 ± 11 kg/m, mean age was 43 ± 5.3 years, and 72% of patients were female. Minimal follow-up was 3 years with a rate of 97%. Both groups were compared for weight loss, comorbidities, quality of life, and complications. RESULTS: Excessive body mass index loss was similar between LSG and LRYGB at each time point (1 year: 72.3 ± 21.9% vs. 76.6 ± 20.9%, P = 0.139; 2 years: 74.7 ± 29.8% vs. 77.7 ± 30%, P = 0.513; 3 years: 70.9 ± 23.8% vs. 73.8 ± 23.3%, P = 0.316). At this interim 3-year time point, comorbidities were significantly reduced and comparable after both procedures except for gastro-esophageal reflux disease and dyslipidemia, which were more successfully treated by LRYGB. Quality of life increased significantly in both groups after 1, 2, and 3 years postsurgery. There was no statistically significant difference in number of complications treated by reoperation (LSG, n = 9; LRYGB, n = 16, P = 0.15) or number of complications treated conservatively. CONCLUSIONS: In this trial, LSG and LRYGB are equally efficient regarding weight loss, quality of life, and complications up to 3 years postsurgery. Improvement of comorbidities is similar except for gastro-esophageal reflux disease and dyslipidemia that appear to be more successfully treated by LRYGB.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Peterli R, Wölnerhanssen BK, Vetter D, et al. Laparoscopic Sleeve Gastrectomy Versus Roux-Y-Gastric Bypass for Morbid Obesity-3-Year Outcomes of the Prospective Randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg. 2017. PMID: 28170356. doi:10.1097/SLA.0000000000001929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。